HISTORY OFFERS many excellent lessons for our science and technology development; but for that we need to know the past. Not the fabled past of mythical times based on folklore and imagined technical prowess, but the more recent history of modern India, when a poor, struggling nation set itself some ambitious targets. One of the more fascinating aspects of this history is the setting up of a penicillin manufacturing factory in the 1950s. Almost anyone with interest in pharmaceuticals knows about Hindustan Antibiotics, the first factory in the Third World to start production of critical drugs in 1954. Few, however, are aware of the ideological battles that were fought as Jawaharlal Nehru pondered the path of development that his newly independent country should pursue, when access to technology was elusive, resources were scarce and drug multinationals were determined to control markets through their know-how and patents. Why is this of any relevance now? Simply because we have not learned the lessons of the past.
What triggered this column's plunge into history was a small news item about the enormous sums the government had spent on procuring vaccines to fight the SARS-COV-2 pandemic. It reflected the concerns that India's first prime minister grappled with while dealing with the question of setting up manufacturing projects in the country and in particular, the penicillin project. The news report of August 4 said the Government of India had spent, till July 31, 2023, a total of ₹36,397 crore on COVID-19 vaccines. The big payout was to the Serum Institute of India, a contract manufacturer for Covishield, the vaccine developed by British multinational AstraZeneca. It received 25,583 crore for 1.3 billion doses, while Bharat Biotech, makers of the indigenously developed Covaxin earned ₹7,301 crore for 35 million doses. These figures reveal how far we are from the goal of self-reliance in pharma that Nehru had hoped for.
この記事は Down To Earth の August 16, 2023 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です ? サインイン
この記事は Down To Earth の August 16, 2023 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です? サインイン
In leading role again
MOVIES AND WEB SERIES ARE ONCE AGAIN BEING SET IN RUSTIC BACKGROUNDS, INDICATING A RECONNECT BETWEEN CINEMA AND THE COUNTRYSIDE
One Nation One Subscription comes at a huge cost
As top US universities scrap big deals with top scientific publishers, India’s ONOS scheme seems flawed and outdated
Return of Rambhog
Bid to revive and sell the aromatic indigenous paddy variety has led to substantial profits for farmers in Uttar Pradesh's Terai region
Scarred by mining
Natural springs of Kashmir drying up due to illegal riverbed mining
Human-to-human spread a mutation away
CANADA IN mid-November confirmed its first human case of avian influenza, with a teenager in the British Columbia being hospitalised after contracting the H5N1 virus that causes the disease. The patient developed a severe form of the disease, also called bird flu, and had respiratory issues. There was no known cause of transmission.
True rehabilitation
Residents of Madhya Pradesh's Kakdi village take relocation as an opportunity to undertake afforestation, develop sustainable practices
INESCAPABLE THREAT
Chemical pollution is the most underrated and underreported risk of the 21st century that threatens all species and regions
THAT NIGHT, 40 YEARS AGO
Bhopal gas disaster is a tragedy that people continue to face
A JOKE, INDEED
A CONFERENCE OF IRRESPONSIBLE PARTIES THAT CREATED AN OPTICAL ILLUSION TO THE REALITY OF A NEW CLIMATE
THINGS FALL APART
THE WORLD HAS MADE PROGRESS IN MITIGATING EMISSIONS AND ADAPTING TO CLIMATE IMPACTS. BUT THE PROGRESS REMAINS GROSSLY INADEQUATE
